• Aung Naing
  • Joud Hajjar

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 995)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Isabella C. Glitza Oliva, Rana Alqusairi
    Pages 43-63
  3. Luis Corrales, Katherine Scilla, Christian Caglevic, Ken Miller, Julio Oliveira, Christian Rolfo
    Pages 65-95
  4. Lucia Masarova, Hagop Kantarjian, Farhad Ravandi, Padmanee Sharma, Guillermo Garcia-Manero, Naval Daver
    Pages 97-116
  5. Anisha B. Patel, Omar Pacha
    Pages 117-129
  6. Akash Jain, Vickie R. Shannon, Ajay Sheshadri
    Pages 131-149
  7. Yun Tian, Hamzah Abu-Sbeih, Yinghong Wang
    Pages 151-157
  8. Yun Tian, Hamzah Abu-Sbeih, Yinghong Wang
    Pages 159-164

About this book


The second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects.

This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions.

Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.


Immunotherapy Translational cancer immunology Vaccine IL-10 ImmunoOncology

Editors and affiliations

  • Aung Naing
    • 1
  • Joud Hajjar
    • 2
  1. 1.MD Anderson Cancer CenterUniversity of TexasHoustonUSA
  2. 2.Baylor College of MedicineTexas Children’s HospitalHoustonUSA

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods